CN1934107A - 作为酪氨酸激酶抑制剂的2-(3-取代芳基)氨基-4-芳基-噻唑 - Google Patents
作为酪氨酸激酶抑制剂的2-(3-取代芳基)氨基-4-芳基-噻唑 Download PDFInfo
- Publication number
- CN1934107A CN1934107A CNA2005800081898A CN200580008189A CN1934107A CN 1934107 A CN1934107 A CN 1934107A CN A2005800081898 A CNA2005800081898 A CN A2005800081898A CN 200580008189 A CN200580008189 A CN 200580008189A CN 1934107 A CN1934107 A CN 1934107A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- randomly
- aryl
- halogen
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54006404P | 2004-01-30 | 2004-01-30 | |
US60/540,064 | 2004-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1934107A true CN1934107A (zh) | 2007-03-21 |
Family
ID=34826177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800081898A Pending CN1934107A (zh) | 2004-01-30 | 2005-01-28 | 作为酪氨酸激酶抑制剂的2-(3-取代芳基)氨基-4-芳基-噻唑 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1711497A1 (fr) |
JP (1) | JP2007519711A (fr) |
KR (1) | KR20060129413A (fr) |
CN (1) | CN1934107A (fr) |
AU (1) | AU2005209485A1 (fr) |
BR (1) | BRPI0507271A (fr) |
CA (1) | CA2554925A1 (fr) |
IL (1) | IL177007A0 (fr) |
NO (1) | NO20063861L (fr) |
NZ (1) | NZ548884A (fr) |
WO (1) | WO2005073225A1 (fr) |
ZA (1) | ZA200606152B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103130792A (zh) * | 2011-11-30 | 2013-06-05 | 江苏正大天晴药业股份有限公司 | 一种2-氨基噻唑类化合物 |
CN103254184A (zh) * | 2013-05-27 | 2013-08-21 | 湖南科技大学 | 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途 |
CN103319467A (zh) * | 2013-06-15 | 2013-09-25 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2358A (en) | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
EP2016070B1 (fr) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibiteurs de la c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
KR101367645B1 (ko) | 2006-04-20 | 2014-02-27 | 얀센 파마슈티카 엔.브이. | C-fms 키나제의 저해제로서의 복소환식 화합물 |
CA2649755C (fr) * | 2006-04-20 | 2014-12-02 | Janssen Pharmaceutica N.V. | Procede d'inhibition de la kinase de c-kit |
WO2008080134A2 (fr) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles utiles en tant qu'inhibiteurs de axl |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
AU2008257158A1 (en) | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles and their use as antiviral agents |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
AU2010204578B2 (en) | 2009-01-16 | 2016-05-12 | Rigel Pharmaceuticals, Inc. | AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
JP5944503B2 (ja) * | 2011-07-27 | 2016-07-05 | エービー サイエンス | 選択的プロテインキナーゼ阻害剤 |
US9290489B2 (en) | 2012-07-06 | 2016-03-22 | Duke University | Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch |
EP2882757B1 (fr) | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Procédé pour la préparation de dérivés d'ester hétérocyclique |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
US10329265B2 (en) | 2014-08-22 | 2019-06-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
EP3439656A4 (fr) | 2016-04-07 | 2020-03-11 | Duke University | Inhibiteurs doubles à petites molécules de trpv4 et trpa1 pour la désinfection et l'anesthésie |
CA3129665A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010082501A (ko) * | 1997-10-27 | 2001-08-30 | 개리 이. 프라이드만 | 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법 |
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
RU2260592C9 (ru) * | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Циклические ингибиторы протеинтирозинкиназ |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
EA007717B1 (ru) * | 2001-08-13 | 2006-12-29 | Янссен Фармацевтика Н.В. | 2-амино-4,5-тризамещенные производные тиазолила |
EP1467981A1 (fr) * | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
CA2494695C (fr) * | 2002-08-02 | 2011-04-05 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit |
PT1635824E (pt) * | 2003-06-03 | 2009-11-24 | Novartis Ag | Inibidores de p-38 à base de heterociclos de 5 membros |
-
2005
- 2005-01-28 EP EP05702517A patent/EP1711497A1/fr not_active Withdrawn
- 2005-01-28 CA CA002554925A patent/CA2554925A1/fr not_active Abandoned
- 2005-01-28 NZ NZ548884A patent/NZ548884A/en unknown
- 2005-01-28 BR BRPI0507271-9A patent/BRPI0507271A/pt not_active IP Right Cessation
- 2005-01-28 KR KR1020067017411A patent/KR20060129413A/ko not_active Application Discontinuation
- 2005-01-28 JP JP2006550363A patent/JP2007519711A/ja active Pending
- 2005-01-28 AU AU2005209485A patent/AU2005209485A1/en not_active Abandoned
- 2005-01-28 WO PCT/IB2005/000401 patent/WO2005073225A1/fr active Application Filing
- 2005-01-28 CN CNA2005800081898A patent/CN1934107A/zh active Pending
-
2006
- 2006-07-20 IL IL177007A patent/IL177007A0/en unknown
- 2006-07-25 ZA ZA200606152A patent/ZA200606152B/xx unknown
- 2006-08-30 NO NO20063861A patent/NO20063861L/no not_active Application Discontinuation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103130792A (zh) * | 2011-11-30 | 2013-06-05 | 江苏正大天晴药业股份有限公司 | 一种2-氨基噻唑类化合物 |
CN103130792B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种2-氨基噻唑类化合物 |
CN103254184A (zh) * | 2013-05-27 | 2013-08-21 | 湖南科技大学 | 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途 |
CN103254184B (zh) * | 2013-05-27 | 2015-03-18 | 湖南科技大学 | 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途 |
CN103319467A (zh) * | 2013-06-15 | 2013-09-25 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
CN103319467B (zh) * | 2013-06-15 | 2015-10-14 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0507271A (pt) | 2007-06-26 |
IL177007A0 (en) | 2006-12-10 |
ZA200606152B (en) | 2007-11-28 |
CA2554925A1 (fr) | 2005-08-11 |
KR20060129413A (ko) | 2006-12-15 |
NZ548884A (en) | 2010-06-25 |
WO2005073225A1 (fr) | 2005-08-11 |
NO20063861L (no) | 2006-10-23 |
EP1711497A1 (fr) | 2006-10-18 |
JP2007519711A (ja) | 2007-07-19 |
AU2005209485A1 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1934107A (zh) | 作为酪氨酸激酶抑制剂的2-(3-取代芳基)氨基-4-芳基-噻唑 | |
CN1950347A (zh) | 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物 | |
CN1684959A (zh) | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 | |
CN100343258C (zh) | 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物 | |
CN1234358C (zh) | 苯并噻唑衍生物 | |
CN1239485C (zh) | 作为IL-1β和TNF-α抑制剂的二苯酮类 | |
CN1273466C (zh) | 具有唑基的喹啉衍生物和喹唑啉衍生物 | |
CN1269813C (zh) | 作为细胞增生抑制剂的咪唑-5-基-2-苯胺基-嘧啶 | |
CN1703408A (zh) | 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺 | |
CN1720049A (zh) | 2-取代的4-杂芳基-嘧啶的治疗用途 | |
CN1805748A (zh) | 作为raf激酶抑制剂的2-氨基嘧啶衍生物 | |
CN1812789A (zh) | 氨磺酰取代的咪唑并喹啉 | |
CN1711266A (zh) | 具有抗增殖活性的嘧啶并化合物(ⅱ) | |
CN1960726A (zh) | 包含jnk抑制剂和环孢菌素的组合物 | |
CN1138773C (zh) | 4-链烯基(和炔基)氧吲哚作为细胞周期蛋白-依赖性激酶尤其是cdk2的抑制剂 | |
CN1886377A (zh) | 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物 | |
CN1742010A (zh) | 新的化学化合物 | |
CN1681810A (zh) | 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物 | |
CN1348370A (zh) | 环状蛋白酪氨酸激酶抑制剂 | |
CN1902171A (zh) | 用作ccr-5拮抗剂的苄醚胺化合物 | |
CN1703405A (zh) | 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物 | |
CN1378537A (zh) | 嘧啶衍生物 | |
CN1926121A (zh) | 噻唑衍生物及其应用 | |
CN1898221A (zh) | Atp-结合弹夹转运蛋白的调控剂 | |
CN1538960A (zh) | 作为激酶抑制剂的氨基-2,3-二氮杂萘酮衍生物,它们的制备方法和含有它们的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1102807 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20070321 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1102807 Country of ref document: HK |